Our pipeline of immune-modulating, clinical-stage product candidates are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation.
Program & Target | Therapeutic Area | Preclinical | Phase 1 | Phase 2 | Phase 3 | Mkt | Rights | |||
---|---|---|---|---|---|---|---|---|---|---|
Rilonacept* IL-1α & IL-1β | Recurrent Pericarditis | End Phase 3 | Worldwide (excluding the Middle East and North Africa) | |||||||
Mavrilimumab** GM-CSFRα | Giant Cell Arteritis | Phase 2 | Worldwide | |||||||
COVID-19 Pneumonia & Hyperinflammation | Phase 2 | Worldwide | ||||||||
Vixarelimab*** OSMRβ | Prurigo Nodularis | Phase 2 | Worldwide | |||||||
KPL-404 CD40 | T-Cell Dependent, B-Cell–Mediated Indications | Phase 1 | Worldwide |